Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoSTU:CUP -5.35%95 Days Payable is 117.88 as of Jun. 2026, which is 10% above its 10-year median of 106.68. GuruFocus rates STU:CUP with a GF Score™ of 95/100 and a GF Value™ of €42.02 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 927 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 58.9% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CUP vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Chugai Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (STU:CUP) has a Days Payable of 117.88 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chugai Pharmaceutical Co and its competitors. This is 10% above median its historical median of 106.68. Over the past decade, Chugai Pharmaceutical Co's Days Payable has ranged from 93.89 to 142.32. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #381 out of 927 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is Chugai Pharmaceutical Co's Days Payable too high?
Chugai Pharmaceutical Co's current Days Payable of 117.88 is 10% above median its 10-year median of 106.68. Over the past 10 years, this metric has ranged from a low of 93.89 to a high of 142.32. The Drug Manufacturers industry median Days Payable is 90.28. Chugai Pharmaceutical Co's value of 117.88 is 30.6% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #381 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #381 out of 927 companies for Days Payable. This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 90.28. Chugai Pharmaceutical Co's value of 117.88 is 30.6% above this benchmark. Historically, Chugai Pharmaceutical Co's own Days Payable has ranged from 93.89 to 142.32 over the past decade. While the company's 10-year median is 106.68 vs. the industry median of 90.28, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Days Payable of 117.88 is 30.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Days Payable is 117.88, which is 10% above median its own 10-year median of 106.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (STU:CUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.02, compared to a current price of €36.79 — trading 12.4% below its estimated fair value. The current Days Payable is 117.88, which is 10% above median its 10-year median of 106.68 and 30.6% above the Drug Manufacturers industry median of 90.28. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chugai Pharmaceutical Co (STU:CUP), the current Days Payable is 117.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (STU:CUP) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of €36.79 is trading 12.4% below its estimated GF Value™ of €42.02.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for STU:CUP:
Days Payable: 117.88 (10% above median its 10-year median of 106.68)
GF Value™: €42.02 vs. price of €36.79 (12.4% below fair value)
Industry Position: 30.6% above the Drug Manufacturers median (#381 of 927)
No single metric tells the full story. See the STU:CUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score
Get the complete analysis for STU:CUP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CUP has been successfully added to your 
